dianabol stack
Dianabol stack of biologically active compounds of Ginkgo dianabol stack extract (flavonoid glycosides, terpene lactones) may reduce vascular permeability, inhibit platelet aggregation. As a consequence, it improves microcirculation, supply of the brain and peripheral tissues of oxygen and glucose.
Indications
The drug is given at the elderly cerebrovascular disorders, accompanied by:
- disorders of attention and / or memory, violation of intellectual abilities,
- anxiety, fear,
- dizziness, tinnitus, sleep disturbances.
Appointed in cases of violation of the circulation of the lower limbs.Contraindications
: Hypersensitivity to the drug, reduced blood clotting, erosive gastritis, gastric ulcer and duodenal ulcer in the acute stage, children’s age (18 years).Dosing and Administration
The drug is given 1 capsule 3 times a day. The capsules should be swallowed with a little water. The course of treatment for at least 3 months. The first signs of improvement usually appear after 1 month. Repeat courses may, after consultation with the doctor.Side effects:
In rare cases, allergic reactions (skin rash), dyspepsia, headache, decreased blood clotting.Use of the drug during pregnancy and lactation
dianabol stack is not recommended during pregnancy and lactationOverdosing
Currently, the cases of drug overdose dianabol stack has not been reported.
dianabol dosage
Dianabol dosage is a selective, non-steroidal anti-androgen without having other types of endocrine activity. It is a racemic mixture of a non-steroidal antiandrogenic activity predominantly (R) -enantiomer. dianabol dosage binds to the androgen receptor and not activate gene expression, suppresses the stimulatory effect of androgens. The result is a regression of prostate tumors. In some patients receiving dianabol dosage cessation may lead to the development of the syndrome of “cancellation” anti-androgens. Dianabol dosage After intake of rapidly and completely absorbed from the gastrointestinal tract. Food intake does not affect absorption. (S) -enantiomer excreted faster (R) -enantiomer of the last half-life – about 7 days. With daily administration of dianabol dosage concentration of (R) -enantiomer in the plasma is increased by about 10 times because of the long half-life, which enables the drug once a day. The daily dose of dianabol dosage receiving 50 mg equilibrium concentration of the (R) enantiomer in the plasma of about 9 mg / ml. When administered 150 mg dianabol dosage daily equilibrium concentration of (R) enantiomer is approximately 22 mcg / mL. In the equilibrium state, about 99% of total circulating enantiomers of the active (R) -enantiomer. The connection to plasma proteins is high (for a racemic mixture of 96% for the (R) enantiomer 99.6%). The intensity and stereospecifically metabolized in the liver (by oxidation and glucuronic acid conjugates). The metabolites are not active, the kidneys and intestines in approximately equal proportions. In the pharmacokinetics (R) -enantiomer does not affect the age, renal impairment, mild to moderate hepatic dysfunction. There is evidence that patients with severely impaired liver function slows down the elimination of (R) enantiomer from plasma.
Indications
- Common prostate cancer in combination with an analogue of gonadotropin-releasing hormone (GnRH) or surgical castration.
- Locally common prostate cancer (TK-T4, any N, MO; T1-T2, N +, MO) as monotherapy or adjuvant therapy in combination with radiotherapy or radical prostatectomy.
- Locally advanced non-metastatic prostate cancer in cases where surgical castration or other medical intervention are not applicable or acceptable.
Contraindications
: Hypersensitivity to any component of the drug, simultaneous reception with terfenadine, astemizole, cisapride, lactase deficiency, lactose intolerance, glucose-galactose malabsorption (product contains lactose); childhood. Should not be administered to patients females. With caution Abnormal liver function.
Dosing and Administration
Inside.
Adult males (including the elderly..): When the prevalence of prostate cancer in combination with a GnRH analogue or surgical castration: 50 mg once daily. Treatment dianabol dosage should be started simultaneously with the start of reception of GnRH analogue or surgical castration. In locally advanced prostate cancer: 150 mg once a day. dianabol dosage should take a long time, for at least 2 years. If signs of progression of the disease taking the drug should be discontinued. Violations nochek function: Dosage adjustment is not required. Violations of the liver: in mild disturbance of function of the liver dose adjustment is required. In patients with moderate and severe hepatic impairment increased accumulation of dianabol dosage can be observed.
Side effects:
The pharmacological action of dianabol dosage may condition the following side effects:
- very common (> 10%): gynecomastia (may persist even after the cessation of therapy, particularly in the case of taking the drug for a long time), thoracic pain glands, “tides” of blood to the face;
- frequent (> 1% and <10%): diarrhea, nausea, transient increase in activity of “liver” transaminases, cholestasis and jaundice (described liver function changes are rarely rated as serious, they were transient in nature, completely disappeared or decreased with continued therapy or after cancellation drug), pruritus, asthenia; when use of the drug in a daily dose of 150 mg – alopecia or hair regrowth, decreased libido, sexual dysfunction, weight gain.
- rare (> 0.1% – <1%): hypersensitivity reactions, including angioedema and urticaria, interstitial lung disease; angina pectoris, prolongation of the interval QT, cardiac arrhythmias; when use of the drug in a daily dose of 150 mg – abdominal pain, depression, dyspepsia, hematuria.
- very rarely (> 0.01% – <0.1%): vomiting, dry skin (when using the drug in a daily dose of 150 mg of dry skin occurs often), liver failure (causal connection with taking dianabol dosage significantly is not installed) thrombocytopenia.
With simultaneous use of dianabol dosage and GnRH analogues can also experience the following adverse events with a frequency of> 1% (causal connection with taking the drug is not installed, some of the noted side effects occurred in elderly patients): Since the cardiovascular system: heart failure. From the digestive system: anorexia, dry mouth, dyspepsia, dysphagia, constipation, flatulence. From the nervous system: dizziness, headache, insomnia, somnolence. respiratory system: shortness of breath. From the urinary system: nocturia, urinary infections tract, dysuria, urinary retention, urinary frequency, polyuria, hydronephrosis. From the hematopoietic system: anemia, leukopenia. On the part of the skin and its appendages: alopecia, rash, sweating, hirsutism. From the laboratory parameters: hyperglycemia, increased activity of “liver” transaminases. Other: abdominal pain, chest pain, pelvic pain, back pain, decreased or increased body weight, edema, diabetes, fever.
Overdose
Cases of overdose have not been described in humans. There is no specific antidote. Treatment is symptomatic. Dialysis is not effective, since dianabol dosage is closely associated with proteins and excreted by the kidneys unchanged. Shown general supportive treatment and monitoring of vital body functions.
Interaction with other medicinal products
There are no data on the pharmacokinetic or pharmacodynamic interactions between dianabol dosage and GnRH analogues.
In in vitro studies have shown that (11) enantiomer of dianabol dosage inhibit CYP ZA4, to a lesser extent affecting the activity of CYP 2C9, 2C19 and 2D6. Potential to dianabol dosage for interaction with other drugs has been detected, but using dianabol dosage for 28 days to patients receiving midazolam, area under the curve “concentration-time» (AUC) midazolam is increased by 80%.
Incompatible with terfenadine, astemizole, cisapride.
caution must be exercised in the appointment of dianabol dosage together with cyclosporine or calcium channel blockers. You may need to decrease the dose of these drugs, particularly in the case or potentiation of side effects. After the start of the use or withdrawal of dianabol dosage is preferably carried out careful monitoring of cyclosporin plasma concentrations and the clinical condition of the patient.
The simultaneous use of dianabol dosage and drugs that inhibit microsomal oxidation of drugs, such as cimetidine or ketoconazole may increase dianabol dosage concentration in blood plasma and possibly to increase the incidence of adverse effects. It enhances the effect of coumarin anticoagulants, including warfarin (competition for protein binding).
Cautions
Given the possibility of slowing down excretion of dianabol dosage in patients with impaired hepatic function it is advisable to periodically assess liver function. Most of the changes of liver function occur in the first six months of treatment with dianabol dosage.
In the case of pronounced changes in hepatic function receiving the drug should be discontinued. In patients with disease progression on higher levels of prostate-specific antigen (PSA) should consider stopping treatment dianabol dosage.
In the appointment of dianabol dosage in patients receiving coumarin anticoagulants should regularly monitor the prothrombin time. Given the possibility of dianabol dosage inhibiting the activity of cytochrome P450 (CYP ZA4), caution should be exercised with concomitant administration of dianabol dosage with drugs primarily metabolized by the CYP ZA4.
Effects on ability to drive vehicles and management mechanisms
In the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Product form
tablets covered with a foil cover, 50 mg and 150 mg. On 14 tablets in blisters of PVC film and aluminum foil. On 2 blisters with instruction on use are placed in a pile of cardboard.
Marking
on blister indicate the number of production licenses and a trademark of the manufacturer, in Russian indicate the name of the drug, dosage form, dosage, lot number, production date, shelf life «in bulk».
The label on the box and the boxes indicate the number of production licenses and trade the manufacturer’s mark on the Russian and English languages indicate the manufacturer, address, country, name of the drug, dosage form, dosage, name and content of active substances in one tablet, storage conditions, batch number, production date, shelf life, ” just for packaging “, the number of tablets in a blister, the number of blisters. When packing at CJSC “Skopinsky pharmaceutical plant” and CJSC “MAKIZ PHARMA”, Russian.
On the pack and the label for packaging in Russian indicate pre-acceptance of the manufacturer, his trademark, country, name of the company in charge of the packaging, its trade sign, address, phone / fax, the owner of the registration certificate, his trademark, address, phone / fax number, drug name, dosage form, dosage, name and content of active substances in one tablet, the number of tablets in the package, the storage conditions, “Apply for doctor’s prescription “,” Keep out of the reach of children “, the batch number, manufacturing date (corresponding to« in bulk »the date of manufacture of the drug), the expiry date. On the bundle further indicate dispensing conditions, method of application, registration number, pharmacotherapy-matic group, a bar code, “Contains lactose monohydrate.” In the group the package label indicates the number of additional packages.
dianabol side effects for men
Dianabol side effects for men selective beta 1-blocker without its own sympathomimetic activity, has no membrane stabilizing action. It lowers blood plasma renin activity, reduces myocardial oxygen demand, slows the heart rate (HR) (at rest and during exercise). It has antihypertensive, antianginal and antiarrhythmic action. Blocking in low doses of beta1-adrenergic receptors of the heart, reduces the formation of catecholamines stimulated cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP), decreases intracellular calcium ion current, has a negative chrono-, Drome, BATM and inotropic effects, inhibits the conductivity and excitability. When has exceeded therapeutic doses of beta 2-adrenoceptor blocking activity. The total peripheral vascular resistance at the beginning of the drug in the first 24 hours, is increased (as a result of reciprocal increase in the activity of alpha-adrenoceptor stimulation and removal of beta2-adrenoceptor), which is 1-3 days it returns to the original and with long-term appointment – is reduced. The hypotensive effect associated with a decrease in cardiac output, sympathetic stimulation of peripheral vascular disease, decreased activity of the renin-angiotensin system (is more important for patients with initial hypersecretion of renin), restoration of sensitivity in response to the decrease in blood pressure (BP ) and the effect on the central nervous system (CNS). When hypertension effect occurs within 2-5 days, stable operation is noted after 1-2 months. Antianginal effect is due to a decrease in myocardial oxygen demand as a result of shortening of the heart rate and reduce myocardial contractility, lengthening of diastole, improving myocardial perfusion.By increasing the end-diastolic left ventricular pressure and increase the tension of muscle fibers of the ventricles can be increased oxygen demand, especially in patients with chronic heart failure. When used in high therapeutic doses, unlike non-selective beta-blocker, has a less pronounced effect on organs containing beta2-adrenergic receptors (pancreas, skeletal muscle, smooth muscle of the peripheral arteries, bronchi and uterus) and carbohydrate metabolism; It does not cause a delay of sodium ions (Na +) in the body; atherogenic action expression is not different from that of propranolol. The antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased cAMP levels, hypertension), decrease in the rate of spontaneous excitation of the sinus and ectopic pacemakers and slowing of the atrioventricular (AV) of (mainly antegrade and to a lesser extent, in the retrograde direction through the AV node) and on additional routes.
Pharmacokinetics
Absorption – 80-90%, does not affect food intake on absorption. The maximum plasma concentration observed after 1-3 hours, the connection with plasma proteins – 26-33%. Permeability through the blood brain barrier and the placental barrier – is low. 50% of the dose is metabolized in the liver with the formation of active metabolites the half-life -. 10-12 hours Approximately 98% is excreted by the kidneys, of which 50% in an unmodified form, less than 2% through the intestines (in the bile).
Indications
- Arterial hypertension;
- Ischemic heart disease: prevention of attacks of stable angina.
Contraindications : Hypersensitivity to dianabol side effects for men or other beta-blockers; shock (including cardiogenic); collapse; pulmonary edema; congestive heart failure; Chronic heart failure decompensation requiring of inotropic therapy;AV blockade II-III degree, without a pacemaker; sinoatrial block; sick sinus syndrome; bradycardia (heart rate less than 60 beats / min..); cardiomegaly (without heart failure); severe hypotension (systolic blood pressure less than 100 mmHg, especially myocardial infarction); severe bronchial asthma and chronic obstructive pulmonary disease (COPD) history; simultaneous reception of monoamine oxidase inhibitors (MAOIs) (except for MAO-B); late stages of peripheral circulation; Reynaud’s syndrome; pheochromocytoma (without simultaneous use of alpha-blockers): metabolic acidosis; age of 18 years (effectiveness and safety have been established); lactose intolerance, lactase deficiency or glucose-galactose malabsorption (lactose as part of the preparation).
Precautions Liver failure; chronic renal failure (creatinine clearance less than 20 mL / min.); myasthenia gravis; hyperthyroidism; diabetes; Prinzmetal angina, AV block of I degree; psoriasis; depression (including history); a history of allergic reactions; adherence to a strict diet; elderly age.
Pregnancy and lactation Application Bidop drug ® during pregnancy is possible only when the intended benefits of therapy for the mother outweighs the potential risk of side effects in the fetus and / or the child. There are no data on whether dianabol side effects for men into breast milk. If necessary, use during lactation should stop breastfeeding.
Dosing and Administration Inside, in the morning on an empty stomach, not liquid, once. The dose should be adjusted individually. Arterial hypertension and coronary heart disease: prevention of attacks of stable angina usually starting dose is 5 mg 1 time a day. If necessary, increase the dose to 10 mg 1 time per day. The maximum daily dose of -20 mg per day. In patients dianabol results with impaired renal function at creatinine clearance (CC) of less than 20 ml / min. or with severe liver problems, the maximum daily dose -. 10 mg . Increasing the dose in such patients should be carried out with extreme caution dose adjustment in elderly patients is not required.
Side effects Side effects observed when using the drug, classified into categories depending on their frequency of occurrence: very common > 1/10; often> 1/100, <1/10; uncommon > 1/1000, <1/100; rare > 1/10000, <1/1000; very rare <1/10000, including isolated reports. On the part of the central nervous system : rarely – fatigue, weakness, fatigue, dizziness, headache, sleep disorders, depression, anxiety, confusion, or short-term memory loss, rarely – hallucinations, myasthenia gravis “nightmarish” dream, seizures (including calves), paresthesia in the extremities (in patients with “intermittent” claudication and Raynaud’s syndrome), tremor. On the part of the organ of vision : rarely – visual disturbances, reduced secretion of tear fluid, dry and sore eyes; very rarely – conjunctivitis. On the part of the cardiovascular system : very often – sinus bradycardia, palpitations; often – marked reduction of blood pressure, the manifestation of vasospasm (strengthening of peripheral blood circulation, cooling of the lower limbs, paresthesia, Raynaud’s syndrome); rarely – orthostatic hypotension, conduction disturbances infarction, AV block (up to the development of a complete transverse blockade and heart failure), arrhythmia, weakening of the myocardial contractility, the development of chronic heart failure (swelling of ankles, feet, shortness of breath), chest pain. On the part of the digestive system : often – dryness of the oral mucosa, nausea, vomiting, abdominal pain, constipation or diarrhea; rarely – liver function abnormalities (dark urine, yellow skin or sclera, cholestasis), changes in taste, hepatitis. With the respiratory system: rarely – shortness of breath when administered at high doses (loss of selectivity) and / or in predisposed patients – laryngo and bronchospasm; seldom – nasal congestion. On the part of the endocrine system : hyperglycemia (in patients with insulin-dependent diabetes), hypoglycemia (in patients receiving insulin), hypothyroid state. Allergic reactions :. rare – pruritus, rash, urticaria For the skin : rarely – increased sweating, flushing of the skin; very rare – rash, psoriasiform skin reactions, exacerbation of psoriasis, alopecia. Laboratory findings : rarely – increased activity of “liver” transaminases (increased alanine aminotransferase, aspartate aminotransferase), hyperbilirubinemia, hypertriglyceridemia; in some cases – thrombocytopenia (unusual bleeding and hemorrhage), agranulocytosis, leukopenia. Effect on the fetus : intrauterine growth retardation, hypoglycemia, bradycardia. Other : rarely – arthralgia; rarely – the weakening of the libido, reduced potency; back pain syndrome “cancel” (increasing angina attacks, increased blood pressure).
Overdose symptoms : arrhythmia, ventricular premature beats, bradycardia, AV block, marked reduction in blood pressure, the development of chronic heart failure, cyanosis of nails and hands, shortness of breath, bronchospasm, dizziness, fainting, seizures, hypoglycemia. Treatment : gastric lavage and the appointment of absorbent ; Symptomatic therapy: which developed at AV blockade – intravenous infusion of 1-2 mg of atropine, epinephrine or staging a temporary pacemaker; with ventricular arrhythmia – lidocaine (IA class of drugs does not apply); In marked decrease in blood pressure – the patient must be dianabol for sale in the Trendelenburg position; if there are no signs of pulmonary edema – intravenous plasma-solutions, with inefficiency – the introduction of epinephrine, dopamine, dobutamine (to maintain, chronotropic, and inotropic effects and eliminate the pronounced reduction in blood pressure); heart failure – cardiac glycosides, diuretics, glucagon; in convulsions – diazepam intravenously; with bronchospasm–beta2 adrenostimulyatorov inhalation.
Interaction with other drugs allergens used for immunotherapy, or allergen extracts for skin tests increase the risk of severe systemic allergic reactions or anaphylaxis in patients receiving dianabol side effects for men.Iodine-containing X-ray contrast agent for intravenous administration increases the risk of anaphylactic reactions. Phenytoin intravenous administration, funds for inhalation anesthesia (derivatives of hydrocarbons) increase the intensity of cardiodepressive action and the likelihood of blood pressure lowering. Modifies the effectiveness of insulin and hypoglycemic agents for oral , masking the symptoms of developing hypoglycemia (tachycardia, increased blood pressure). Reduces the clearance of lidocaine and xanthine (except theophylline) and increases their concentration in the blood plasma, especially in patients with initially increased clearance of theophylline under the influence of smoking. Antihypertensive effect of weakening non-steroidal anti-inflammatory drugs (delay of sodium ions (Na +) and the blockade of prostaglandin synthesis by the kidneys), corticosteroids, and estrogens (delay of ions Na +). Cardiac glycosides, methyldopa, reserpine and guanfacine blockers “slow” calcium channel blockers (verapamil, diltiazem), amiodarone and other antiarrhythmic drugs increase the risk of developing or worsening of bradycardia, AV block, cardiac arrest and heart failure. Nifedipine can lead to a significant reduction in blood pressure. Diuretics, clonidine, sympatholytic , hydralazine and other antihypertensive drugs may lead to an excessive reduction in blood pressure. Extends the action of non-depolarizing muscle relaxants and anticoagulant effect of coumarin . tri- and tetracyclic antidepressants, antipsychotics (neuroleptics), ethanol, sedatives and hypnotics increase central nervous system depression. not recommended simultaneous application with MAO inhibitors (except MAO-B, see. “Contraindications”), due to the significant increase in the hypotensive action, a break in treatment between receiving MAO inhibitors (except MAO-B) and dianabol side effects for men must not be less than 14 days. Negidrirovannye ergot alkaloids increase the risk of peripheral circulatory disorders. Ergotamine increases the risk of peripheral circulatory disorders; rifampin shortens the half-life.
Cautions
monitoring patients receiving Bidop ® , should include measurement of heart rate and blood pressure (at the beginning of treatment -. Daily, then 1 every 3-4 months) holding an electrocardiogram, determination of blood glucose concentration of diabetic patients (1 in 4 times 5 months.). In elderly patients, it is recommended to monitor renal function (1 time in 4-5 months.). It is necessary to train the patient’s heart rate calculation method and instruct on the need of medical advice in heart rate less than 50 bpm. / Min. Before treatment recommended study of respiratory function in patients with a history of bronchopulmonary history. Approximately 20% of patients with angina Beta-blockers are ineffective. The main reasons -. Marked coronary atherosclerosis with a low threshold of ischemia (.. Heart rate less than 100 beats / min) and a higher end-diastolic volume of the left ventricle, which violates the subendocardial blood flow . At the “smokers” the effectiveness of beta-blockers lower Patients who use contact lenses, must be taken into account that in the context of treatment may decrease the production of tear fluid. When used in patients with pheochromocytoma have a risk of paradoxical hypertension (if not previously reached effective alpha adrenoblockade). When thyrotoxicosis Bidop ® may mask certain clinical signs of hyperthyroidism (eg, tachycardia). Abrupt withdrawal in patients with thyrotoxicosis is contraindicated because the symptoms can increase. In diabetes may mask tachycardia caused by hypoglycemia. In contrast, nonselective beta-blockers practically no increase insulin-induced hypoglycemia and delay recovery of blood glucose to normal levels. At the same time taking clonidine its reception can be terminated only a few days after the cancellation Bidop drug ® . Increased severity of hypersensitivity reactions are possible and the lack of effect of conventional doses of epinephrine (adrenaline) with aggravated allergic history. In the case of the need for a planned surgical treatment abolition of the drug is carried out for 48 hours before general anesthesia. If the patient has taken the drug before surgery, he should choose the drug for general anesthesia with minimal negative inotropic effect. Reciprocal activation of the vagus nerve can be eliminated by intravenous administration of atropine (1-2 mg). Drugs that reduce stocks of catecholamines (including reserpine ), may enhance the effect of beta-blockers, so patients taking such drug combinations should be under constant medical supervision in order to identify pronounced reduction in blood pressure and bradycardia. patients with bronhospasticheskimi diseases can assign cardioselective blocker in case of intolerance and / or ineffectiveness of other antihypertensive means. Overdosing is dangerous development of bronchospasm. In the case of elderly patients increasing bradycardia (less than 50 u. / Min.), Pronounced reduction in blood pressure (systolic blood pressure below 100 mm Hg), AV blockade bronchospasm, ventricular arrhythmias, severe violations of the liver and kidney is necessary to reduce the dosage or discontinue treatment. It is recommended to discontinue therapy in the development of depression. Do not abruptly discontinue the treatment because of the risk of severe arrhythmias and myocardial infarction. Abolition are gradually reducing the dose for 2 weeks or more (reduce dose by 25% in 3-4 days).It is necessary to cancel prior to the study in blood and urine catecholamines and Normetanephrine vanilinmindalnoy acid; titers of antinuclear antibodies.
Effects on ability to drive vehicles and operate machinery during treatment dizziness, especially early in therapy, and therefore must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Composition Tablets 5 mg, 10 mg. By 14 tablets in blister PVC / PVDC / Al. At 1.2 or 4 blisters with instruction for use in a cardboard box.
buy hgh china
dianabol steroids
Dianabol steroids – selective beta1-blocker without intrinsic sympathomimetic activity. It has no membrane stabilizing (local anesthetic) activity. When topically applied dianabol steroids reduces both elevated and normal intraocular pressure due to decreased production of intraocular fluid.The onset of the hypotensive effect is usually observed after 30 minutes of use of the drug, and maximum decrease in IOP occurs in about 2 h. After a single impact on the installation ophthalmotonus maintained for 12 hours. dianabol steroids, compared with other beta-blockers, do not cause a decrease in blood flow in the optic nerve. dianabol steroids causes miosis, accommodation spasm, night blindness (unlike miotikov).
Pharmacokinetics
dianabol steroids highly lipophilic, resulting in good penetration through the cornea into the anterior chamber of the eye, the maximum concentration (C max ) is defined in the front chamber 20 minutes after the installation. When applied topically dianobal, systemic absorption is low, the plasma concentration is below the threshold (2 ng / ml) detected. Communication with plasma proteins – 50%. The half-life (T?) -. 14-22 hours excreted by the kidneys (15% unchanged). The permeability of the blood-brain barrier (BBB) and the placental barrier – low secretion of breast milk – small.
Indications
- ocular hypertension;
- chronic open form of glaucoma;
- angle-closure glaucoma (in combination with miotikami).
Contraindications
- hypersensitivity to the drug;
- sinus bradycardia;
- atrioventricular block II and III degree;
- sick sinus syndrome;
- Children up to age 18 years (due to lack of efficacy and safety data).
Carefully
- Diabetes, hyperthyroidism, concomitant use of oral beta-blockers, Raynaud’s syndrome, pheochromocytoma, bronchial asthma, chronic obstructive bronchitis, atrioventricular block I degree, heart failure.
Pregnancy and lactation Use of the drug during pregnancy and lactation (breastfeeding) is possible only when the intended benefits to the mother outweighs the potential risk to the fetus or child.
Dosing and Administration Locally. 1 -2 eye drops into the conjunctival sac 2 times a day. In some patients, the stabilization of intraocular pressure occurs within a few weeks, so it is recommended to control intraocular pressure within the first month of treatment buy primabol. If the desired level of intraocular pressure is not achieved during monotherapy Betoftanom should assign additional therapy.
Side effects: Local : short-term discomfort in the eyes after instillation, watery eyes; . in some cases – reduction in corneal sensitivity, redness of the eye, keratitis, photophobia, anisocoria, blurred vision, itching, a feeling of “dryness” of the eye, allergic reactions Systemic side effects are rare. On the part of the central nervous system (CNS) : dizziness, nausea, sonlivosg , insomnia, headache, depression, increased symptoms of myasthenia gravis. Since the cardiovascular system : bradycardia, cardiac conduction and heart failure. The respiratory system : dyspnea, bronchospasm, asthma, respiratory failure.
Overdosing
Currently, the cases of overdose were reported Betoftana. When injected into an excess amount of the drug must be the eyes flush eyes with warm water. In case of overdose beta1-blockers may occur: hypotension, bradycardia, congestive heart failure. Treatment is symptomatic.
Interaction with other drugs With simultaneous use of the drug Betoftan and adrenaline for oftalmologicheskogoprimeneniya solution in individual cases may develop mydriasis. When using Betoftan drug in combination with drugs that deplete catecholamines (such as reserpine), may be observed amplification effects such as lowering blood pressure (BP) and bradycardia. with the simultaneous use of the drug Betoftan and beta-blockers for griema inside, increases the risk of side effects (both local and systemic) due to the additive effect. caution should be exercised when co-use of the drug Betoftan and adrenergic psychotropic drugs because of possible enhance their action. When concomitant administration danabol of muscle relaxants and hypoglycemic agents strengthen their actions can be observed. In a joint application with sympathomimetics -. Strengthening their vasoconstrictor effect can be used in combination with other topical ophthalmic medications as needed. In this case, the interval between their use should be at least 10 minutes.
Cautions Betoftan contains the preservative benzalkonium chloride, which can be adsorbed soft contact lenses and have a damaging effect on the eye tissue. Therefore, patients wearing soft contact lenses, remove them before applying drops and set back no earlier than 20 minutes after instillation. To avoid contamination of the pipette, do not touch your eyes with instillation. Diabetes Mellitus: Beta-blockers should be used with caution in patients with a tendency to hypoglycemia, as these medications can mask the symptoms of acute hypoglycemia. Thyrotoxicosis: Beta-blockers may mask some of the symptoms of hyper-tireoza ( eg, tachycardia). In patients with suspected hyperthyroidism should not abruptly cancel beta-blockers, as this may cause increase in symptoms. Myasthenia : Beta-blockers can cause symptoms similar to those of myasthenia gravis (eg, diplopia, ptosis, generalized weakness). Surgery : Before elective surgery beta-blockers should be gradually (not simultaneously!) canceled 48 hours prior to general anesthesia, as during general anesthesia may reduce myocardial sensitivity to sympathetic stimulation dianabol steroids, required for the heart. Pulmonary : caution should be exercised in the appointment of beta- blockers in patients with severely reduced function of the respiratory system. Despite the fact that clinical studies have shown no effect of dianabol steroids on respiratory function, should not exclude the possibility of hypersensitivity to the drug. The risk of an anaphylactic reaction : patients taking beta-blockers, may have a history of atopy or anaphylactic reactions. In the case of repeated reactions, such patients may not be sensitive to the usual doses of adrenaline necessary for relief of anaphylaxis. In installations drug can enter the systemic circulation. Thus, there may be side effects are the same as in the intravenous and parenteral administration of beta-blockers. Betoftan has minimal effect on blood pressure and heart rate. However, caution should be exercised in the appointment of his patients with atrioventricular block I degree, or heart failure. Treatment should be discontinued at the first signs of decompensation of the cardiovascular system. Patients who after the installation of the drug is temporarily reduced the clarity of vision, it is not recommended to engage in activities that require attention and response to his recovery.
Product form Eye drops 0.5%. In 5 ml of solution in a white polymer bottle-dropper indoor polymer cap with safety ring. One dropper bottle with instructions for use in a carton box. Acheter steroide anabolisant musculation, ou acheter des steroides en france danger des steroides anabolisants.
dianabol before and after
Dianabol before and after – selective beta1-blocker without intrinsic sympathomimetic activity. It has no membrane stabilizing (local anesthetic) activity.
When topically applied dianabol before and after reduces both elevated and normal intraocular pressure, due to reduced production of intraocular fluid. The onset of the antihypertensive effect generally occurs within 30 minutes after instillation, and the maximum reduction of intraocular pressure occurs approximately 2 hours.After a single impact on the installation ophthalmotonus maintained for 12 hours. dianabol before and after, compared with other beta-blockers, do not cause a decrease in blood flow in the optic nerve.
dianabol before and after causes miosis, accommodation spasm, night blindness, the effect of “veil” before the eyes (unlike miotikov).
Pharmacokinetics dianabol before and after highly lipophilic, resulting in good penetration through the cornea into the anterior chamber, anterior chamber Cmax determined 20 minutes after instillation. When applied topically, systemic absorption is low, the plasma concentration is below the threshold (2 ng / ml) detected. Excretion mainly through the kidneys.
Indications
Reduction of intraocular pressure as monotherapy or in combination with other drugs:
– at elevated intraocular pressure,
– with open-angle glaucoma.
Contraindications
Individual hypersensitivity to the drug.
Sinus bradycardia, atrioventricular block II-III degree, cardiogenic shock, heart failure, heart failure, a history of sick sinus syndrome in patients with artificial pacemaker, children up to 18 years.
Carefully
Thyrotoxicosis, myasthenia gravis, diabetes, Raynaud’s syndrome, pheochromocytoma, concomitant use of oral beta-blockers.
Pregnancy and breast-feeding
Fertility
Data on the effect of the drug Betoptik ® C on human fertility are not available. Pregnancy should not be used during pregnancy except in cases where it is really necessary. Sufficient experience of use of the drug during pregnancy is not. According to the results of epidemiological studies, malformativnyh effects have been identified, but with oral β-blockers there is risk of delay fetal development. In addition, signs and symptoms of .beta.-blockade (such as bradycardia, hypotension, respiratory distress and hypoglycaemia) were detected in the neonatal period in cases where the .beta.-blockers adopted mother before giving birth. It is necessary to carry out careful monitoring of babies during the first days of life if the drug Betoptik ® C, used by the mother during pregnancy. Information on the reduction of systemic absorption, see. in the “dosage and Administration”. breastfeeding β-blockers are excreted in breast milk and may cause serious adverse reactions in breast-fed infants. However, it is unlikely that the application of therapeutic doses Betoptik drug ® C, a sufficient amount of the drug to be present in breast milk to cause the development of clinical symptoms of β-blockade in the newborn. Can be used for the treatment of nursing mothers prescribed by a doctor, if the expected therapeutic benefits exceed the risk development of possible side effects. Information on the reduction of systemic absorption, see. in the “Dosing and administration”.
Dosing and Administration
Locally. Before use, the vial shaken!
According 1-2 eye drops into the conjunctival sac 2 times per day.
Recommended after instillation of the preparation the lacrimal canaliculi clamped at the inner corner of the eye (1-2 minutes). To reduce the risk of systemic side effects
in some patients the intraocular stabilization pressure occurs within a few weeks, so it is recommended to control intraocular pressure within the first month of treatment.
If the desired level of intraocular pressure is not achieved during monotherapy, combination therapy should be assigned.
Side effect
Violations of the organ of vision
is very common in 10% of cases there is discomfort in the eyes.
Often, in 1-10% of cases, there is a blurred vision, increased lacrimation.
Infrequently, in 0.1-1% of cases, punctate keratitis, keratitis, conjunctivitis , blepharitis, blurred vision, photophobia, eye pain, dry eye, asthenopia, blepharospasm, itching of the eye, eye discharge, crusting on the edges of the eyelids, inflammation, eye irritation, a violation of the conjunctiva, conjunctival edema, hyperemia of the eye.
Rarely, in 0.01-0.1% of the cases, there was a cataract.
The frequency is not known: redness of the eyelids.
Disorders of the nervous system
. Often, a headache
. Occasionally, syncope
is unknown frequency: dizziness
Violations of the heart
. It is not often, bradycardia, tachycardia
Frequency not known: arrhythmia
Violations by vessels
Rare: hypotension.
Disorders of the respiratory system, organs, thoracic and mediastinal disorders
Uncommon: asthma, dyspnea, rhinitis.
Rare: cough, rhinorrhea.
Disorders of the gastrointestinal tract
Uncommon: nausea.
Rare: dysgeusia.
Disorders of the skin and subcutaneous tissue disorders
Rare:. Dermatitis, rash
Frequency not known: Alopecia
Violations of the genital and breast
Rare: loss of libido.
Mental disorders
Rare:. Anxiety
unknown frequency: Insomnia, depression.
Violations by the immune system
Frequency unknown: hypersensitivity
General disorders and administration site reactions
Frequency unknown: asthenia.
In the application of β-blockers (eye drops) were observed, and other adverse reactions, that may develop during use of the drug and Betoptik ® C:
Violations of the immune system: systemic allergic reactions, including angioedema, urticaria, local and generalized rash, pruritus, anaphylactic reaction.
Violations of the Metabolism and nutrition:
Hypoglycemia
Mental disorders
nightmares, memory loss.
Disorders of the nervous system
cerebrovascular disorders, cerebral ischemia, worsening of symptoms of signs and symptoms of myasthenia gravis, paresthesia.
Violations by the authority of
detachment choroidal after filtration surgery, decreased corneal sensitivity, corneal erosion, ptosis, diplopia.
Disturbances of cardiac
chest pain, palpitations, edema, congestive heart failure, AV block, cardiac arrest, heart failure.
Violations of the vessels:
Raynaud’s phenomenon, cold hands and feet.
Disorders of the respiratory system, organs, thoracic and mediastinal disorders
bronchospasm (predominantly in patients with bronchospastic disease in history)
Violations of the gastrointestinal
dyspepsia, diarrhea, dry mouth, abdominal pain, vomiting
Violations of the track and subcutaneous tissue
psoriazoformnaya rash or exacerbation of psoriasis
Violations of the genital and breast
sexual dysfunction
General disorders and administration site reactions
Fatigue
Overdose
When injected into an excess amount of the drug is recommended eyes flush eyes with warm water.
If accidentally taking the drug inside the symptoms of β1-blocker overdose are: bradycardia, hypotension, acute cardiac insufficiency and bronchospasm. Treatment is symptomatic and supportive.
Interaction with other drugs
Patients receiving the drug Betoptik ® C and at the same time taking other β-blockers are administered orally, the risk of adverse reactions (both system and local) may be higher due to possible additive effects. These patients should be under close medical supervision.
When concomitant administration of β-blockers for topical ophthalmic use with oral forms of calcium channel blockers, β-blockers, anti-arrhythmic drugs (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine and drugs deplete catecholamines such as reserpine, may be observed amplification effects such as lowering blood pressure and bradycardia.
in some cases, as a result of the simultaneous application of β-blockers and adrenaline (epinephrine) may develop mydriasis.
When concomitant administration of muscle relaxants and hypoglycemic agents may be a strengthening of their actions .
.beta.-blockers may impair the effect of adrenaline, used in anaphylactic reactions. It should be used with extreme caution in patients with atopy or anaphylaxis in history.
In a joint application with sympathomimetics -. Strengthening their vasoconstrictor effect
should be taken when the joint application of dianabol before and after and adrenergic psychotropic drugs as a result of the possible increase in their actions.
Can be used in combination with other, if necessary topical ophthalmic preparations. In this case, the interval between their use should be at least 10 minutes.
special instructions
Diabetes: .beta.-blockers should be used with caution in patients with a tendency to spontaneous hypoglycemia and diabetics labile currents, since these drugs may mask the signs and symptoms of acute hypoglycemia. Thyrotoxicosis: .beta.-blockers may mask some of the symptoms of hyperthyroidism (eg, tachycardia). In patients with suspected hyperthyroidism should not be abruptly cancel β-blockers, as this may cause increase in symptoms. Myasthenia gravis: β-blockers may cause signs and symptoms similar to those in infants (eg, diplopia, ptosis, generalized weakness). Surgery : the anesthetist should be advised that the patient takes dianabol before and after. Before elective surgery β-blockers should be gradually (not simultaneously!) Canceled 48 hours prior to general anesthesia because during general anesthesia may reduce myocardial sensitivity to sympathetic stimulation necessary for the operation of the heart (for example, they can block the effect of systemic β-agonist adrenaline). Pulmonary: Caution should be exercised in the appointment of β-blockers in patients with severely reduced function of the respiratory system. Despite the fact that clinical studies have shown no effect of dianabol before and after on respiratory function, should not exclude the possibility of hypersensitivity to the drug. The risk of an anaphylactic reaction: patients taking β-blockers may have a history of atopy or anaphylactic reactions. In the case of repeated reactions, such patients may be sensitive to the usual doses of adrenaline needed for the relief of anaphylaxis. dianabol before and after should be used with caution in patients with severely impaired peripheral circulation (ie with Raynaud’s syndrome and pheochromocytoma). The local assignment β-blockers can enter the systemic circulation. Thus, .beta.-blockers can cause cardiovascular, pulmonary and other adverse reactions, as well as by intravenous and parenteral administration. Cases of severe respiratory and cardiovascular disorders, including the death of bronchospasm in patients with asthma and death from heart failure. Violations of the heart: in patients with cardiovascular diseases (eg, coronary heart disease, Prinzmetal angina, heart failure) and hypotension .beta.-blocker therapy should be critically assessed and considered the possibility of the treatment of other active substances. It is necessary to closely monitor for signs of worsening disease and adverse reactions in patients suffering from cardiovascular diseases. Corneal diseases: .beta.-blockers can cause dry eyes. It should be used with caution in patients with corneal diseases. Detachment of the choroid: . Described cases of detachment of the choroid with the use of drugs that prevent the formation of intraocular fluid (eg, timolol, acetazolamide) after filtration operations preparation Betoptik ® C contains the preservative benzalkonium chloride, which can cause eye irritation and discoloration of soft contact lenses. Avoid direct contact of the product with soft contact lenses. Patients who use contact lenses, the lenses before applying the drug should be removed and set them back no earlier than 15 minutes after instillation of the drug. Do not touch the tip of the dropper bottle to any surface to avoid contamination of the vial and its contents. The vial must be closed after each use.
Effects on ability to drive vehicles and management mechanisms
Patients who after instillation of the drug is temporarily reduced sharpness of vision or other visual disturbances occur, it is not recommended to engage in activities that require attention and response to its recovery.
